HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): G. Varela Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Novoa, N. Articles by Jiménez, M.F. Search for Related Content PubMed PubMed Citation Articles by Novoa, N. Articles by Jiménez, M.F. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2001;20:700-704
© 2001 Elsevier Science NL

Morbidity after surgery for non-small cell lung carcinoma is not related to neoadjuvant chemotherapy

Section of Thoracic Surgery, Salamanca University Hospital, Paseo San Vicente 58, 37007 Salamanca, Spain

Received 6 May 2001; received in revised form 5 June 2001; accepted 17 June 2001.

Corresponding author. Tel.: +34-923-291-383; fax: +34-923-291-383
e-mail: ctorax{at}usal.es

Objectives: To compare postoperative morbidity and mortality rates in two groups of operated non-small cell lung carcinoma patients (NSCLC) with or without induction chemotherapy. Methods: This is a case–control study on 42 cases and 42 controls. Cases (Group A) underwent induction chemotherapy. Chemotherapy indications and regimens were variable. Control cases (Group B) were randomly selected among 494 NSCLC comparable patients operated on in the same period of time. The selection criteria for operation were the same in both groups. Dependent outcomes were operative death and complications. Independent selected variables were: age, co-morbidity, predicted postoperative FEV1% (1 s forced expiratory volume in percentage), type of surgery and clinical and pathological staging. All postoperative events and independent variables were prospectively registered. Chi-square and risk calculations on contingence tables and one-way ANOVA have been tested. Results: Both series are comparable in demographics, preoperative variables and type of surgery. No mortality has been registered. In Group A, the overall morbidity was 26.2% (11 out of 42 cases), and in Group B, this was 42.9% (18 out of 42 cases; P=0.084). Morbidity was not related to the type of surgery (pneumonectomy vs. other; P=0.205 in Group A and P=0.08 in Group B). Pathological staging did not influence the postoperative outcome, either in Group A (P=0.72; odds ratio, 1.515; 95% confidence interval (CI), 0.375–6.122) or Group B (P=0.299; odds ratio, 0.4; 95% CI, 0.089–1.797). Conclusions: Induction chemotherapy in NSCLC has no influence on postoperative morbidity.

Key Words: Non-small cell lung carcinoma • Neoadjuvant chemotherapy • Morbidity

This article has been cited by other articles:

				T. A. d'Amato, A. S. Ashrafi, M. J. Schuchert, D. S.A. Alshehab, A. J.E. Seely, F. M. Shamji, D. E. Maziak, S. R. Sundaresan, P. F. Ferson, J. D. Luketich, et al. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann. Thorac. Surg., October 1, 2009; 88(4): 1079 - 1085. [Abstract] [Full Text] [PDF]

				A. Brunelli, A. Charloux, C. T. Bolliger, G. Rocco, J-P. Sculier, G. Varela, M. Licker, M. K. Ferguson, C. Faivre-Finn, R. M. Huber, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Eur. Respir. J., July 1, 2009; 34(1): 17 - 41. [Abstract] [Full Text] [PDF]

				T. J. Kuzniar, M. G. Blum, K. Kasibowska-Kuzniar, and G. M. Mutlu Predictors of Acute Lung Injury and Severe Hypoxemia in Patients Undergoing Operative Talc Pleurodesis Ann. Thorac. Surg., December 1, 2006; 82(6): 1976 - 1981. [Abstract] [Full Text] [PDF]

				F. Leo, P. Solli, G. Veronesi, D. Radice, A. Floridi, R. Gasparri, F. Petrella, A. Borri, D. Galetta, and L. Spaggiari Does chemotherapy increase the risk of respiratory complications after pneumonectomy? J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 519 - 523. [Abstract] [Full Text] [PDF]

				A. Brunelli, F. Xiume', M. Al Refai, M. Salati, R. Marasco, and A. Sabbatini Gemcitabine-Cisplatin Chemotherapy Before Lung Resection: A Case-Matched Analysis of Early Outcome Ann. Thorac. Surg., June 1, 2006; 81(6): 1963 - 1968. [Abstract] [Full Text] [PDF]

				F. Leo, A. Borri, F. Petrella, R. Gasparri, D. Galetta, G. Veronesi, and L. Spaggiari Preoperative Chemotherapy and Postoperative Complications: A Closer Look Ann. Thorac. Surg., June 1, 2006; 81(6): 2335 - 2335. [Full Text] [PDF]

				C. Doddoli, F. Barlesi, D. Trousse, S. Robitail, S. Yena, P. Astoul, R. Giudicelli, P. Fuentes, and P. Thomas One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 416 - 425. [Abstract] [Full Text] [PDF]

				G. Varela, N. Novoa, M.F. Jimenez, and G. Santos Applicability of logistic regression (LR) risk modelling to decision making in lung cancer resection Interactive CardioVascular and Thoracic Surgery, March 1, 2003; 2(1): 12 - 15. [Abstract] [Full Text] [PDF]